Evidence map›Paper›PMID 24621953›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014

Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial.

Joaniter I Nankabirwa, Bonnie Wandera, Pauline Amuge, Noah Kiwanuka, Grant Dorsey, Philip J Rosenthal, Simon J Brooker, Sarah G Staedke, Moses R Kamya

4 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 77 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 4 pooled it
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01231880 phase3completednot on this map

School-based Malaria Control: Impact of Intermittent Preventive Treatment on Malaria Morbidity and Cognitive Function in Ugandan School Children

TypeinterventionalSponsorMakerere UniversityRan2011 to 2012Enrolled740ConditionsMalariaArmsFour monthly IPT with dihydroartemisinin Piperaquine (DP), Monthly IPT using DP, Placebo given every month
NCT02009215 phase4completednot on this map

'SCHOOL-BASED TREATMENT WITH ACT TO REDUCE TRANSMISSION' (START-IPT): Evaluation of the Community Impact of Intermittent Preventive Treatment for Malaria in Ugandan Children: a Cluster Randomised Trial

TypeinterventionalSponsorLondon School of Hygiene and Tropical MedicineRan2014 to 2015Enrolled10,746ConditionsMalariaArmsDihydroartemisinin-piperaquine (DP)
NCT02315690 phase3completednot on this mapstarted 2015, after this paper: background citation

Evaluating the Effectiveness and Feasibility of Reactive Focal Mass Drug Administration vs. Reactive Case Detection as a Community Level Intervention in Response to a Passively Identified Index Malaria Case in Swaziland

TypeinterventionalSponsorUniversity of California, San FranciscoRan2015 to 2017Enrolled4,000ConditionsMalariaArmsdihydroartemisinin-piperaquine (DHAp), reactive case detection
NCT04660110 phase3unknown statusnot on this mapstarted 2021, after this paper: background citation

Evaluation of the Household-level Impact of a Single Round of Intermittent Preventive Treatment of Malaria in Schoolchildren: A Randomized Study

TypeinterventionalSponsorMakerere UniversityRan2021 to 2021Enrolled1,500ConditionsMalariaArmsIPT with Dihydroartemisinin Piperaquine
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 4 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Dihydroartemisinin-Piperaquine Chemoprevention and Malaria Incidence After Severe Flooding: Evaluation of a Pragmatic Intervention in Rural Uganda.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Joaniter I NankabirwaDepartment of Medicine, Makerere University College of Health Sciences.
Bonnie Wandera
Pauline Amuge
Noah Kiwanuka
Grant Dorsey
Philip J Rosenthal
Simon J Brooker
Sarah G Staedke
Moses R Kamya
Infectious Diseases Research Collaboration · UGMakerere University · UGLondon School of Hygiene & Tropical Medicine · GBSan Francisco General Hospital · USUniversity of California, San Francisco · US

Funding

Resistance of Malaria Parasites to Artemisinin-Based TherapiesR01AI075045 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2009 to 2024
$8.4M
Training In Malaria Research in UgandaD43TW007375 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2005 to 2019
$2.9M
Uganda Malaria COHRE Training ProgramD43TW008077 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI KAMYA, MOSES ROBERT · 2009 to 2013
$777k
FIC NIH HHS D43 TW007375FIC NIH HHS D43 TW008077FIC NIH HHS TW007375FIC NIH HHS TW008077NIAID NIH HHS R01 AI075045Wellcome Trust 087540Wellcome Trust 098045
6 · The paper itself

Abstract

backgroundIntermittent preventive treatment (IPT) in schoolchildren offers a promising option for malaria control. However, the optimal drug and dosing regimens for IPT remain to be determined.

methodsWe conducted a randomized, double-blind, placebo-controlled trial in 740 schoolchildren aged 6-14 years living in a setting of high malaria transmission in Uganda. Enrolled children were randomized to dihydroartemisinin-piperaquine (DP) given once a month (IPTm), DP given once a school term (4 treatments over 12 months, IPTst), or placebo and followed for 12 months. The primary outcome was the incidence of malaria over 12 months. Secondary outcomes included parasite prevalence and anemia over 12 months. Analyses were conducted on an intention-to-treat basis.

resultsIn the placebo arm, the incidence of malaria was 0.34 episodes per person-year and the prevalence of parasitemia and anemia was 38% and 20%, respectively. IPTm reduced the incidence of malaria by 96% (95% confidence interval [CI], 88%-99%, P < .0001), the prevalence of asymptomatic parasitemia by 94% (95% CI, 92%-96%, P < .0001), and the prevalence of anemia by 40% (95% CI, 19%-56%, P < .0001). IPTst had no significant effect on the incidence of symptomatic malaria or the prevalence of anemia, but reduced the prevalence of asymptomatic parasitemia by 54% (95% CI, 47%-60%, P < .0001).

conclusionsMonthly IPT with DP offered remarkable protection against clinical malaria, parasitemia, and anemia in schoolchildren living in a high-malaria-transmission setting. CLINICAL TRIALS REGISTRATION: NCT01231880.

Indexed as

AnemiaAntimalarialsArtemisininsChildDouble-Blind MethodDrug Administration ScheduleDrug CombinationsFemaleHumansMalariaMalaria, FalciparumMaleParasitemiaPiperazinesPrevalenceQuinolinesAntimalarialsArtemisininsartenimolDrug CombinationspiperaquinePiperazinesQuinolinesintermittent preventive treatmentmalariaschoolchildren

Identifiers

PMID24621953
PMCPMC4001293
OpenAlexW2162712812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.